<DOC>
	<DOCNO>NCT00836888</DOCNO>
	<brief_summary>Evaluation safety , tolerability pharmacokinetics ( PK ) single dose multiple dos ONO-4538 Japanese patient advanced malignant solid tumor , exploratory evaluation pharmacological effect efficacy ONO-4538 .</brief_summary>
	<brief_title>ONO-4538 Phase I Study Patients With Advanced Malignant Solid Tumors Japan</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological cytological diagnosis solid tumor least one measurable lesion ≥ 10mm . Tumor must advance recurrent refractory standard therapy alternative , appropriate therapy exists . ECOG Performance Status 01 Life expectancy ≥ 3 month Other inclusion criterion specify study protocol History severe hypersensitivity reaction antibody . Residual adverse reaction effect prior therapy , deem affect safety evaluation study drug investigator subinvestigator . Two synchronous tumor , except adequately treat basal cell cancer cancer situ , superficial bladder cancer , cancer patient diseasefree least 5 year . Patients active autoimmune disease document history chronic recurrent autoimmune disease , current medical condition require systemic immunosuppressive dos steroid immunosuppressive medication . Other exclusion criterion specify study protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>ONO-4538</keyword>
	<keyword>MDX-1106</keyword>
	<keyword>solid tumor</keyword>
</DOC>